AC
PRQR icon

Ascend Capital’s ProQR Therapeutics PRQR Stock Holding History

Ascend Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-52,235
Closed -$869K – 160
2015
Q2 		$869K Buy
52,235
+22,235
+74% +$419K 0.03% 136
2015
Q1 		$656K Sell
30,000
-60,000
-67% -$1.24M 0.02% 156
2014
Q4 		$1.95M Buy
+90,000
New +$1.37M 0.07% 144

Other funds holding PRQR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

Ascend Capital's PRQR Position: Q3 2015 in Review

Ascend Capital sold out of ProQR Therapeutics (PRQR) in Q3 2015, closing a stake of 52,235 shares — an estimated $869K sold.

Ascend Capital first reported a position in PRQR in Q4 2014 and held it in 3 quarters. The position peaked at $1.95M in Q4 2014. 37 funds tracked by Wall St. Rank hold PRQR as of Q3 2015.

  • Ascend Capital reported no remaining ProQR Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Ascend Capital sold 52,235 ProQR Therapeutics shares in Q3 2015, an estimated $869K.
  • Ascend Capital first reported a position in ProQR Therapeutics in Q4 2014 and held it in 3 quarters.
  • Ascend Capital's ProQR Therapeutics position peaked at $1.95M in Q4 2014.
  • 37 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2015.

Based on Ascend Capital's 13F filing for Q3 2015, filed 13 Nov 2015.